Belarus Bans Sales of 47 E-cigarette Products for Health Concerns

Regulations by 2FIRSTS.ai
Mar.05.2024
Belarus Bans Sales of 47 E-cigarette Products for Health Concerns
Belarus bans sale of 47 e-cigarettes due to health risks, including nicotine overdose and lack of safety information.

Recently, according to the Truth Report of the Communist Youth League, the State Standardization Bureau of Belarus has banned the sale of 47 types of e-cigarettes in the market. Media reports cited the information from the Gomel Branch of the State Standardization Bureau of Belarus, stating that after regulatory measures in January and February of this year, it was found that some e-cigarettes being sold in the Gomel market did not meet legislative requirements.

 

According to a statement released by the news department, the ban on the 47 e-cigarette series is due to their potential and evident health risks.

 

The e-cigarettes with problems include e-liquids that contain excessive nicotine (exceeding the limit of 20mg per milliliter) and e-liquids that have five times the legal capacity (exceeding the 2ml limit). In addition, some e-cigarette products lack expiration date information, usage restriction warnings, disease contraindications, and information on potential illnesses that may be caused. Some e-cigarette products even fail to provide relevant documents on product compliance and safety. "Using these e-cigarettes will directly threaten the health of consumers," the Belarusian State Standardization Agency emphasized.

 

The non-compliant products have been taken off the shelves and administrative penalties have been imposed on the sellers.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Russia’s State Duma May Soon Consider Full Ban on Vape Sales
Russia’s State Duma May Soon Consider Full Ban on Vape Sales
Russia’s State Duma will soon consider a proposal to impose a complete ban on the sale of vapes. The move follows President Vladimir Putin’s endorsement of a nationwide prohibition. Lawmaker Aleksey Volotskov said vape use has surged by 52% since early 2025, with illegal products now dominating 80% of the market.
Nov.11 by 2FIRSTS.ai
British American Tobacco’s VELO Launches Limited McLaren F1 Edition: US Price Only 60% of EU/UK
British American Tobacco’s VELO Launches Limited McLaren F1 Edition: US Price Only 60% of EU/UK
BAT’s VELO has released a McLaren F1 co-branded, track-themed limited-edition pack in McLaren’s orange-black livery. Pricing is about $4.60 per can in the U.S. versus ~$7.40 in the EU/UK. The collaboration extends BAT’s partnership with McLaren dating back to 2019.
Oct.11 by 2FIRSTS.ai
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
According to media reports, a leaked European Commission document indicates the EU plans to push for its strictest regulatory framework on nicotine and tobacco products at COP11 in Switzerland this November, including measures such as a full ban on nicotine pouches and flavoured products.
Oct.10 by 2FIRSTS.ai
R.J. Reynolds Seeks Dismissal of “Carbon Neutral” Lawsuit over Vuse E-Cigarette Claims
R.J. Reynolds Seeks Dismissal of “Carbon Neutral” Lawsuit over Vuse E-Cigarette Claims
R.J. Reynolds Vapor Co. has moved to dismiss a class-action lawsuit alleging false “carbon neutral” claims for its Vuse e-cigarettes, arguing its statements were based on independent certifications from Verra and Vertis, not misleading consumers.
Oct.23 by 2FIRSTS.ai
Japan Tobacco Expands Ploom Aura EVO Menthol Line With Two New Products and One Upgraded Blend
Japan Tobacco Expands Ploom Aura EVO Menthol Line With Two New Products and One Upgraded Blend
Japan Tobacco Inc. (JT) has added two new EVO sticks, Evo Black Menthol and Evo Fresh Mint, to its Ploom Aura lineup and reformulated Evo Cold Menthol, creating a menthol range with three distinct levels of cooling intensity and flavor profile.
Dec.01 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai